Form 10-Q CYTRX CORP For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to Form 10-Q CYTRX CORP For: Jun 30
August 7, 2014 11:28 AM EDT
Aegis Capital affirms its Buy rating and $12 target price on CytRx Corp. (Nasdaq: CYTR) following Q2 results and update.
Analyst Ram Selvaraju commented, The firm ended the quarter with $102.5mm in cash, which we expect to be sufficient to fund operations well into 2016, past a... More
August 7, 2014 6:09 AM EDT
CytRx (Nasdaq: CYTR) announced that its oral presentation given by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center, titled Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas, was featured in The Lancet Oncology in its July 2014 issue (Volume 15, Issue 8) in a review of the major presentations from the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
We are honored to have been included in The Lancet Oncologys... More
August 6, 2014 6:10 AM EDT
CytRx Corp (NASDAQ: CYTR) reported Q2 EPS of ($0.28), $0.08 worse than the analyst estimate of ($0.20).
For earnings history and earnings-related data on CytRx Corp (CYTR) click here.
...
More
